Nektar Therapeutics (NKTR)

33.40
NASDAQ : Health Technology
Prev Close 34.03
Day Low/High 33.23 / 34.24
52 Wk Low/High 29.22 / 69.76
Avg Volume 1.59M
Exchange NASDAQ
Shares Outstanding 174.31M
Market Cap 5.93B
EPS 4.00
P/E Ratio 8.64
Div & Yield N.A. (N.A)
First-in-Human Data Presented From Phase 1a Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology

First-in-Human Data Presented From Phase 1a Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology

MADRID and SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in...

Nektar Therapeutics To Host Webcast Conference Call With Immunology Expert For Analysts & Investors During 2019 European Congress Of Rheumatology (EULAR 2019)

Nektar Therapeutics To Host Webcast Conference Call With Immunology Expert For Analysts & Investors During 2019 European Congress Of Rheumatology (EULAR 2019)

SAN FRANCISCO, June 11, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00 a.

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

The company says the test revealed patients were experiencing 'deepening and durability of response over time' with the treatment.

Nektar Therapeutics Presents Biomarker And Clinical Data From PIVOT-02 Phase 2 Study Of Bempegaldesleukin With Nivolumab At 2019 ASCO Annual Meeting

Nektar Therapeutics Presents Biomarker And Clinical Data From PIVOT-02 Phase 2 Study Of Bempegaldesleukin With Nivolumab At 2019 ASCO Annual Meeting

CHICAGO, June 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois.

Nektar Announces The Launch Of Inheris Biopharma, Inc.

Nektar Announces The Launch Of Inheris Biopharma, Inc.

Key Assets will Include NKTR-181, a Novel, First-in-Class, Investigational Opioid

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.

McDonald's, Kinder Morgan, Intel: 'Mad Money' Lightning Round

McDonald's, Kinder Morgan, Intel: 'Mad Money' Lightning Round

Jim Cramer is taking a closer look at McDonald's, Kinder Morgan, Intel, Nektar Therapeutics, L Brands, Scientific Games, and more.

Nektar Therapeutics Announces Five Accepted Abstracts At 2019 American Society Of Clinical Oncology's (ASCO) Annual Meeting

Nektar Therapeutics Announces Five Accepted Abstracts At 2019 American Society Of Clinical Oncology's (ASCO) Annual Meeting

SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 31 to...

Nektar Therapeutics Reports Financial Results For The First Quarter Of 2019

Nektar Therapeutics Reports Financial Results For The First Quarter Of 2019

SAN FRANCISCO, May 8, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019.

Nektar Therapeutics Expected to Lose 69 Cents a Share

Nektar Therapeutics Expected to Lose 69 Cents a Share

Nektar Therapeutics revenue expected to fall 27.2% to $27.7 million.

Nektar To Announce Financial Results For The First Quarter 2019 On Wednesday, May 8, 2019, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The First Quarter 2019 On Wednesday, May 8, 2019, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, May 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019, after the close of U.

What Can't Amazon Do?: Cramer's 'Mad Money' Recap (Monday 4/15/19)

What Can't Amazon Do?: Cramer's 'Mad Money' Recap (Monday 4/15/19)

Amazon seems nearly unstoppable, says Jim Cramer. So be careful if you own something that could be in the retail giant's crosshairs.

Nektar Therapeutics Presents Preclinical Data On Its Immuno-Oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

Nektar Therapeutics Presents Preclinical Data On Its Immuno-Oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist, and NKTR-255,...

Vaccibody AS And Nektar Therapeutics Present New Preclinical Data From Their Immuno-Oncology Collaboration At The American Association For Cancer Research (AACR) Annual Meeting 2019

Vaccibody AS And Nektar Therapeutics Present New Preclinical Data From Their Immuno-Oncology Collaboration At The American Association For Cancer Research (AACR) Annual Meeting 2019

OSLO, Norway and SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.

Nektar Therapeutics To Webcast Presentation At The Cowen And Company 39th Annual Health Care Conference

Nektar Therapeutics To Webcast Presentation At The Cowen And Company 39th Annual Health Care Conference

SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.

Nektar Therapeutics Presents Preliminary Immune Activation, Safety And Clinical Activity Data From The Ongoing Dose-Escalation Stage Of The REVEAL Study At 2019 ASCO-SITC Meeting

Nektar Therapeutics Presents Preliminary Immune Activation, Safety And Clinical Activity Data From The Ongoing Dose-Escalation Stage Of The REVEAL Study At 2019 ASCO-SITC Meeting

SAN FRANCISCO, March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262, a...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADSK, BDC, HLNE, HRI, NKTR, SNV Downgrades: AYX, HMN, IDCC, TPRE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics Reports Fourth Quarter And Year-End 2018 Financial Results

Nektar Therapeutics Reports Fourth Quarter And Year-End 2018 Financial Results

SAN FRANCISCO, Feb. 28, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018.

Nektar Therapeutics Becomes #3 Most Shorted S&P 500 Component, Replacing Iron Mountain

Nektar Therapeutics Becomes #3 Most Shorted S&P 500 Component, Replacing Iron Mountain

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Nektar Therapeutics Announces Several Preclinical Data Presentations For Its Immuno-oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

Nektar Therapeutics Announces Several Preclinical Data Presentations For Its Immuno-oncology Pipeline Candidates At The American Association For Cancer Research (AACR) Annual Meeting 2019

SAN FRANCISCO, Feb. 27, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist,...

Nektar Therapeutics Expected to Lose 55 Cents a Share

Nektar Therapeutics Expected to Lose 55 Cents a Share

Nektar Therapeutics revenue expected to fall 53% to $44.8 million.

Nektar Therapeutics To Webcast Conference Call For Analysts And Investors At The 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Nektar Therapeutics To Webcast Conference Call For Analysts And Investors At The 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

SAN FRANCISCO, Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr.

Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2018 On Thursday, February 28, 2019, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2018 On Thursday, February 28, 2019, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, Feb. 21, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018, on Thursday, February 28, 2019, after the close of U.

Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed The Company According To Shareholder Lawsuit

Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed The Company According To Shareholder Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Nektar Therapeutics.

Clinical Data Presented From PIVOT-02 Study Of Bempegaldesleukin (NKTR-214) With Nivolumab In Metastatic Urothelial Carcinoma Patients At The 2019 ASCO Genitourinary Cancers Symposium

Clinical Data Presented From PIVOT-02 Study Of Bempegaldesleukin (NKTR-214) With Nivolumab In Metastatic Urothelial Carcinoma Patients At The 2019 ASCO Genitourinary Cancers Symposium

Analyst conference call with urothelial cancer specialist to be held at 2:00 p.m. Pacific Time today

Nektar Therapeutics To Webcast Conference Call With Urothelial Cancer Specialist For Analysts & Investors At The 2019 ASCO Genitourinary Cancers Symposium

Nektar Therapeutics To Webcast Conference Call With Urothelial Cancer Specialist For Analysts & Investors At The 2019 ASCO Genitourinary Cancers Symposium

SAN FRANCISCO, Feb. 11, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.

The New #12 Most Shorted S&P 500 Component: Nektar Therapeutics

The New #12 Most Shorted S&P 500 Component: Nektar Therapeutics

The most recent short interest data has been released for the 12/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

Jim Cramer: Do You Believe Ugly Ducklings Can Turn Back Into Swans?

Jim Cramer: Do You Believe Ugly Ducklings Can Turn Back Into Swans?

I see a lot of winners here because of hindsight.

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

ImaginAb Announces Immuno-Oncology License And Clinical Trial Collaboration With Nektar Therapeutics

Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines

TheStreet Quant Rating: C (Hold)